No Data
No Data
BridgeBio Pharma Is Maintained at Overweight by Piper Sandler
BridgeBio Pharma Q1 Loss Widens, Revenue Drops
BridgeBio Pharma Analyst Ratings
Express News | BridgeBio Pharma Shares up 6.1% After Q1 Sales of Heart Condition Drug Beat Estimates
UBS Adjusts Price Target on BridgeBio Pharma to $72 From $65, Maintains Buy Rating
A Quick Look at Today's Ratings for BridgeBio Pharma(BBIO.US), With a Forecast Between $50 to $67